Severe Intraocular Inflammation Following Intravitreal Faricimab.

ABSTRACT:

Importance

Monitoring for and reporting potential cases of intraocular inflammation (IOI) in clinical practice despite limited occurrences in clinical trials, including experiences with relatively new intravitreal agents, such as brolucizumab, pegcetacoplan, or faricimab, helps balance potential benefits and risks of these agents.

Objective

To provide descriptions of 3 initially culture-negative cases of acute, severe, posterior-segment IOI events occurring within the same month following intravitreal faricimab injections at a single institution.

Design, setting, and participants

In this case series, 3 patients manifesting acute, severe IOI following intravitreal injection of faricimab were identified between September 20, 2023, and October 20, 2023.

Exposure

F

SUBMITTER: Thangamathesvaran L 

PROVIDER: S-EPMC10905372 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature